Previous 10 | Next 10 |
2023-10-13 15:47:48 ET Intercept Pharmaceuticals, which agreed to be sold to Sanofi ( NASDAQ: SNY ) late last month, quickly dropped 3% amid a new report from the European Medicines Agency. The study failed to show that Ocaliva was more effective than placebo (a dummy trea...
NEW YORK, NY / ACCESSWIRE / October 4, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Intercept Pharmaceuticals, Inc. (NAS...
NEW YORK, NY / ACCESSWIRE / October 1, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Intercept Pharmaceuticals, Inc. (NA...
2023-09-30 16:00:00 ET More on Intercept Pharma Intercept Pharmaceuticals: Alfasigma Pays Premium For M&A Deal That Suits All Parties Intercept: Narrowed Market, Concentrated Strategy (Rating Upgrade) Canaccord cuts Intercept to hold, calls Alfasigma deal "best p...
NEW YORK, NY / ACCESSWIRE / September 29, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Applied Molecular Transport Inc....
NEW YORK, NY / ACCESSWIRE / September 29, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Intercept Pharmaceuticals, In...
NEW YORK, NY / ACCESSWIRE / September 27, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Intercept Pharmaceuticals, Inc. ...
2023-09-27 06:52:40 ET DENVER, Colo., Sept 27, 2023 ( www.247marketnews.com )- The following stocks are the top performing U.S. stocks over the past week; Vaccitech (NASDAQ: VACC), Siyata Mobile (NASDAQ: SYTA), Soleno Therapeutics (NASDAQ: SLNO), Femasys (NASDAQ: FEMY), Immunovant (NASD...
2023-09-26 18:57:20 ET More on Intercept Pharma Intercept Pharmaceuticals: Alfasigma Pays Premium For M&A Deal That Suits All Parties Intercept: Narrowed Market, Concentrated Strategy (Rating Upgrade) Intercept Pharma unlikely to see rival offers, other roadblock...
2023-09-26 16:29:38 ET More on Intercept Pharma Seeking Alpha’s Quant Rating on Intercept Pharma Intercept Pharmaceuticals: Alfasigma Pays Premium For M&A Deal That Suits All Parties Intercept: Narrowed Market, Concentrated Strategy (Rating Upgrade) ...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...